S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
Log in
NASDAQ:SRNE

Sorrento Therapeutics Stock Forecast, Price & News

$10.78
+1.02 (+10.45 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.32
Now: $10.78
$11.15
50-Day Range
$6.17
MA: $9.78
$18.82
52-Week Range
$1.39
Now: $10.78
$19.39
Volume60.08 million shs
Average Volume27.17 million shs
Market Capitalization$2.61 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.93
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company also develops CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; carcinoembryonic antigen CAR-T cell therapy for the treatment of liver metastases of pancreatic cancer; and various human antibodies. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Read More
Sorrento Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRNE
CUSIPN/A
Phone858-203-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.43 million
Book Value$0.20 per share

Profitability

Net Income$-292,070,000.00
Net Margins-760.19%

Miscellaneous

Employees382
Market Cap$2.61 billion
Next Earnings Date11/13/2020 (Estimated)
OptionableOptionable
$10.78
+1.02 (+10.45 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

How has Sorrento Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Sorrento Therapeutics' stock was trading at $1.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SRNE shares have increased by 468.6% and is now trading at $10.52.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Sorrento Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sorrento Therapeutics
.

When is Sorrento Therapeutics' next earnings date?

Sorrento Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Sorrento Therapeutics
.

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics Inc (NASDAQ:SRNE) released its quarterly earnings data on Tuesday, August, 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.02. The biopharmaceutical company earned $9.01 million during the quarter, compared to the consensus estimate of $7.90 million. Sorrento Therapeutics had a negative return on equity of 490.67% and a negative net margin of 760.19%.
View Sorrento Therapeutics' earnings history
.

What price target have analysts set for SRNE?

3 Wall Street analysts have issued 12-month price targets for Sorrento Therapeutics' stock. Their forecasts range from $21.00 to $30.00. On average, they anticipate Sorrento Therapeutics' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 137.6% from the stock's current price.
View analysts' price targets for Sorrento Therapeutics
.

Are investors shorting Sorrento Therapeutics?

Sorrento Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 73,350,000 shares, an increase of 35.7% from the August 15th total of 54,060,000 shares. Based on an average daily volume of 39,780,000 shares, the days-to-cover ratio is currently 1.8 days.
View Sorrento Therapeutics' Short Interest
.

Who are some of Sorrento Therapeutics' key competitors?

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Moderna (MRNA), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), NVIDIA (NVDA), Tesla (TSLA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB).

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the following people:
  • Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 55)
  • Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 69)
  • Mr. George K. Ng, Corp. Sec. (Age 45)
  • Mr. Jiong Shao M.B.A., CFA, Exec. VP & CFO (Age 51)
  • Ms. Deborah H. Telman, Sr. VP & Gen. Counsel

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.04%), Cormorant Asset Management LP (2.69%), Coatue Management LLC (0.56%), Nuveen Asset Management LLC (0.34%), Goldman Sachs Group Inc. (0.32%) and Bank of New York Mellon Corp (0.27%).
View institutional ownership trends for Sorrento Therapeutics
.

Which institutional investors are selling Sorrento Therapeutics stock?

SRNE stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Integrated Wealth Concepts LLC, UBS Group AG, Donald L. Hagan LLC, Virtus ETF Advisers LLC, SG Americas Securities LLC, and Rathbone Brothers plc.
View insider buying and selling activity for Sorrento Therapeutics
.

Which institutional investors are buying Sorrento Therapeutics stock?

SRNE stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Cormorant Asset Management LP, Coatue Management LLC, Cubist Systematic Strategies LLC, Nuveen Asset Management LLC, Swiss National Bank, Bank of New York Mellon Corp, and Raymond James & Associates.
View insider buying and selling activity for Sorrento Therapeutics
.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $10.52.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $2.55 billion and generates $31.43 million in revenue each year. The biopharmaceutical company earns $-292,070,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Sorrento Therapeutics employs 382 workers across the globe.

What is Sorrento Therapeutics' official website?

The official website for Sorrento Therapeutics is www.sorrentotherapeutics.com.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.